Synopsis

A multicenter, prospective, randomized controlled trial evaluated the effectiveness of differential target multiplexed SCS (DTM SCS) compared to traditional SCS during a 12-month period. Back pain responder rate (≥50% relief) of 80% with DTM SCS at the primary endpoint (3-month) was superior to the back pain responder rate of traditional SCS (51%). The response was sustained for 12 months (84% vs 51%). Furthermore, 69% of subjects receiving DTM SCS experienced profound back pain response (≥80% relief) compared to 35% of subjects receiving traditional SCS. Additional benefits were observed in quality of life, extent of disability, perceived improvement of change, and satisfaction.

Disclosures

MF: Consulting Fee from Abbott, Biotronik, Braeburn, Cornerloc, Medtronic, Nevro; Contracted Research with Abbott, Lumbrera, Medtronic, SGX Medical, Thermaquil; Ownership Interest at Celeri Health, Thermaquil.
PSK: Consulting Fee from Biotronik; Speaker/Teacher with Medtronic.
DP: Consulting Fee from Avanos, Boston Scientific, Esteve, Heron, Medtronic, Nevro; Contracted Research with Abbott, Avanos, Medtronic, Nevro.
RV: Consulting Fee from Medtronic; Speakers Bureau with Medtronic; Ownership Interest at SGX Medical

Julian Naranjo MD

Pain Medicine Specialist, South Florida Clincial Research

Appearances